Company profile · free preview
Ultragenyx
RARE · Updated 10/26/2026
Revenue
$673.0M
Fiscal 2025
Net income
(575.0M)
Fiscal 2025
Free cash flow
(472.0M)
Fiscal 2025
Net cash / (debt)
—
Fiscal 2025
Five-year financials
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $673.0M | $560.2M | $434.2M | $363.3M | $351.4M |
| Net income | (575.0M) | (569.2M) | (606.6M) | (707.4M) | (454.0M) |
| Diluted EPS | — | — | — | — | — |
| Operating cash flow | (466.0M) | (414.2M) | (474.8M) | (380.5M) | (338.7M) |
| Free cash flow | (472.0M) | (421.7M) | (519.1M) | (496.6M) | (411.8M) |
| Cash | $421.0M | $173.7M | $213.6M | $132.9M | $307.6M |
| Total debt | — | — | — | — | — |
Where the cash went
Cumulative, fiscal 2021–2025, straight from the reported cash-flow statements.
Reinvested in capex
—
of operating cash flow
Returned to owners
—
of free cash flow (buybacks + dividends)
Diluted share count
—
change 2021–2025
Capital expenditure $247.0MBar width = share of $247.0M (spending exceeded operating cash flow)
| Operating cash flow | ($2.1B) |
| Capital expenditure | ($247.0M) |
| Free cash flow | ($2.3B) |
| Share buybacks | — |
| Dividends paid | — |
| Acquisitions (net) | — |
| Net debt issued / (repaid) | — |
| Stock-based compensation (non-cash) | — |
"—" means a year didn't report that line, so no total is shown rather than an estimate.
SEC filings
- 10-K · period 2025-12-312026-02-18EDGAR
Ask anything about Ultragenyx's filings
"What changed since last year?" "Where is the cash going?" Get answers drawn straight from the filings.
Start researching freeMore companies
SLB SLBMaxLinear, Inc. MXLBIO-key International, Inc. BKYIPR PRALM ALMDream Finders Homes DFHGH GHLMT LMTDXYZ DXYZTRP TRPFortinet, Inc. FTNTBHP Group BHPSTAK STAKARLO ARLOCSCO CSCOTM TMPFSA PFSAConcentra Group Holdings Parent, Inc. CONJPMorgan Equity Premium Income ETF JEPIJoint Stock Company Kaspi.kz KSPIVelo3D, Inc. VELOResideo Technologies, Inc. REZIImperial Brands PLC IMBBYSphere Entertainment Co. SPHR